Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Belgium
Clinical trial register · European Union · CTIS

Clinical Trials in Belgium, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2556 most recently authorised of 12893 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Nov 2026, 03:17 UTC
2556
Shown in this register
most recently authorised
12,893
Total on CTIS
full historical archive
785
Phase III
within the shown window
Top member states
Spain 1069 France 921 Germany 906 Italy 769 Poland 620 Netherlands 547

Trials with a site in Belgium

456 of 2556 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I
Argenx
Respiratory Tract Diseases
Belgium
18/11/2026
Phase II
JJP BIOLOGICS Sp. z o.o.
Female Urogenital Diseases and Pregnancy Complications
Germany, Belgium, Sweden, Spain, Lithuania
17/11/2026
Phase II
AbbVie Deutschland GmbH & Co. KG
Digestive System Diseases
Netherlands, Belgium, Greece, Spain, Lithuania, Germany, Czechia, Italy, Portugal, Sweden
17/11/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Spain, Belgium, France, Germany, Czechia, Greece
16/11/2026
Phase III
Pulmovant Inc.
Cardiovascular Diseases
France, Netherlands, Germany, Latvia, Sweden, Portugal, Belgium, Lithuania, Czechia, Greece
16/11/2026
Phase II
Solstice Oncology Inc.
Neoplasms
Belgium, Netherlands, Italy
16/11/2026
Phase II
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
France, Netherlands, Belgium, Spain, Germany, Italy, Slovakia, Sweden, Czechia, Lithuania, Greece, Portugal
16/11/2026
Phase II
GlaxoSmithKline Biologicals
Respiratory Tract Diseases
Belgium
13/11/2026
Phase III
Rapport Therapeutics Inc.
Nervous System Diseases
Netherlands, Austria, Czechia, Belgium, Slovakia, Finland, Poland, Spain, Ireland, Sweden, Germany, Hungary, Denmark, Italy, Portugal
11/11/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Germany, Italy, Portugal, Netherlands, Belgium, Hungary
10/11/2026
Phase IV
Subcutaneous Infliximab for perianal fistulizing Crohn’s disease
2026-525879-41-00Fistulizing perianal Crohn’s disease
Centre hospitalier universitaire de Liege
Digestive System Diseases
Belgium
10/11/2026
Phase II
UCB Biopharma
Respiratory Tract Diseases
Poland, Ireland, Belgium, Portugal, Italy, France, Spain, Bulgaria, Germany
10/11/2026
Phase III
Novartis Pharma AG
Neoplasms
Czechia, Portugal, Germany, Austria, Poland, Belgium, Spain, Netherlands, Italy, France, Slovakia
10/11/2026
Phase III
Centessa Pharmaceuticals UK Limited
Nervous System Diseases
Italy, Spain, Germany, Finland, Belgium, France, Poland, Austria
09/11/2026
Phase I
CRISPR Therapeutics AG
Nervous System Diseases
Germany, Austria, Spain, Belgium
09/11/2026
Phase II
UCB Biopharma
Respiratory Tract Diseases
Italy, Netherlands, Poland, Belgium, Spain, France, Czechia, Bulgaria, Germany, Slovakia
09/11/2026
Phase I
Pfizer Inc.
Immune System Diseases
Belgium
09/11/2026
Phase III
Priovant Therapeutics Inc.
Skin and Connective Tissue Diseases
Belgium, Czechia, Poland, Netherlands, France, Italy, Spain, Hungary, Germany
06/11/2026
Phase I
Pfizer Inc.
Nervous System Diseases
Belgium
05/11/2026
Phase I
Merck Sharp & Dohme LLC
Nervous System Diseases
Belgium
04/11/2026
Phase III
Priovant Therapeutics Inc.
Skin and Connective Tissue Diseases
Germany, Austria, Netherlands, Spain, Belgium, Italy, France
04/11/2026
Phase III
Nektar Therapeutics
Skin and Connective Tissue Diseases
Lithuania, Slovakia, Bulgaria, Greece, Czechia, Poland, Spain, Belgium, Germany
03/11/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Nervous System Diseases
Hungary, Belgium, Lithuania, Spain, France, Germany, Netherlands, Poland, Denmark, Slovakia, Italy, Austria, Bulgaria, Portugal, Greece, Czechia, Sweden
30/10/2026
Phase II
Bicara Therapeutics Inc.
Neoplasms
Netherlands, Spain, France, Italy, Belgium, Poland, Germany
30/10/2026
Phase I
Neurocrine Switzerland GmbH
Hormonal diseases
Belgium
29/10/2026
Phase I
Argenx
Musculoskeletal Diseases
Slovenia, Latvia, Denmark, Germany, Belgium, Norway, Spain, Poland, Lithuania, Italy, France, Netherlands
27/10/2026
Phase II
Verastem Inc.
Neoplasms
France, Spain, Germany, Italy, Belgium
27/10/2026
Phase II
Agomab Spain S.L.U.
Respiratory Tract Diseases
Poland, France, Belgium, Italy, Spain, Portugal, Netherlands, Germany
27/10/2026
Phase III
Celcuity Inc.
Neoplasms
Finland, Bulgaria, Portugal, Germany, Greece, Romania, Poland, Hungary, Czechia, Italy, Denmark, Belgium, France, Spain
27/10/2026
Phase II
F. Hoffmann-La Roche AG
Nervous System Diseases
Spain, Belgium, Denmark, France, Poland, Italy, Germany, Ireland
27/10/2026
Phase I
Sanofi-Aventis Recherche & Developpement
Nervous System Diseases
Belgium
26/10/2026
Phase I/II
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Germany, Spain, France, Poland, Belgium, Netherlands
26/10/2026
Phase I
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Belgium
23/10/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Respiratory Tract Diseases
Belgium, France, Netherlands, Finland, Italy, Spain, Germany, Poland, Austria
21/10/2026
Phase I/II
SOTIO Biotech a.s.
Neoplasms
Czechia, Spain, France, Belgium
20/10/2026
Phase III
AstraZeneca AB
Musculoskeletal Diseases
Netherlands, Belgium, Bulgaria, Romania, Italy, Germany, Austria, Spain, Portugal, Greece, Czechia, Poland, France
20/10/2026
Phase III
Glaxosmithkline Research & Development Limited
Immune System Diseases
France, Belgium, Italy, Spain, Austria, Germany, Netherlands, Portugal, Poland, Greece
19/10/2026
Phase III
Hopital Erasme
Hemic and Lymphatic Diseases
France, Belgium
19/10/2026
Phase II
LYSARC
Hemic and Lymphatic Diseases
Belgium, France
16/10/2026
Phase II
Ns Pharma Inc.
Respiratory Tract Diseases
Italy, Greece, Portugal, France, Belgium, Germany, Spain
16/10/2026
Phase II
Novartis Pharma AG
Immune System Diseases
Portugal, Bulgaria, Belgium, Spain, Denmark, France, Slovakia, Poland, Hungary, Italy, Netherlands, Germany, Austria
15/10/2026
Phase IV
Ziekenhuis Oost Limburg
Cardiovascular Diseases
Belgium
13/10/2026
Phase III
Glaxosmithkline Research & Development Limited
Nutritional and Metabolic Diseases
Netherlands, Germany, Austria, France, Spain, Italy, Bulgaria, Poland, Belgium, Greece
13/10/2026
Phase III
Ferrer Internacional S.A., Prilenia Therapeutics B.V.
Nervous System Diseases
Spain, Italy, Portugal, Poland, France, Netherlands, Germany, Belgium, Czechia
12/10/2026
Phase III
Glaxosmithkline Research & Development Limited
Nutritional and Metabolic Diseases
Netherlands, Greece, Austria, Spain, Italy, France, Belgium, Bulgaria, Germany, Poland
12/10/2026
Phase III
Revolution Medicines Inc.
Neoplasms
Austria, Netherlands, Germany, Sweden, Spain, Belgium, Norway, France, Italy
12/10/2026
Phase II
Ns Pharma Inc.
Respiratory Tract Diseases
France, Germany, Poland, Italy, Belgium, Spain, Greece
08/10/2026
Phase III
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
Italy, Austria, Greece, Ireland, Bulgaria, Poland, Sweden, Belgium, Germany, Spain, Czechia, France, Romania, Hungary
08/10/2026
Phase III
Vor Biopharma Inc.
Immune System Diseases
Poland, Spain, Hungary, Italy, Netherlands, Romania, Belgium, France, Bulgaria, Germany
06/10/2026
Phase III
Harmony Biosciences Management Inc.
Nervous System Diseases
France, Germany, Belgium, Spain, Italy, Poland
06/10/2026
Phase II
Argenx
Not possible to specify
Spain, Poland, Czechia, Belgium, Italy
05/10/2026
Phase II
Merck Sharp & Dohme LLC
Neoplasms
Belgium, Spain, Denmark, Italy, France
05/10/2026
Phase I/II
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Poland, France, Belgium, Germany, Netherlands, Spain
05/10/2026
Phase IV
Crohn’s disease Longitudinal Evaluation of Anti-fibrotic Response to UPadacitinib
2025-523038-16-00Crohn’s disease with ileal stricturing complication
UZ Leuven
Investigative Techniques
Spain, Germany, Belgium
01/10/2026
Phase I
Pfizer Inc.
Immune System Diseases
Belgium
30/09/2026
Phase I
Merck Sharp & Dohme LLC
Immune System Diseases
Belgium
30/09/2026
Phase I
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
2024-518348-19-00Advanced Breast cancer (HER2+, HR+/HER2-negative or TNBC), …
Novartis Pharma AG
Neoplasms
France, Italy, Spain, Portugal, Germany, Belgium
29/09/2026
Phase III
Insmed Inc.
Cardiovascular Diseases
Germany, Hungary, Belgium, France, Italy, Sweden, Austria, Poland, Lithuania, Spain, Romania, Greece
29/09/2026
Phase III
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Portugal, Germany, Italy, Czechia, Austria, Spain, Belgium, Netherlands, Poland, Sweden, Greece, Latvia, Hungary, Bulgaria, Romania
29/09/2026
Phase III
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Spain, Slovakia, Hungary, Czechia, Romania, Estonia, Austria, France, Belgium, Sweden, Italy, Latvia, Poland, Bulgaria, Greece, Germany, Denmark, Lithuania, Netherlands
29/09/2026
Phase III
Agios Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Italy, France, Belgium, Ireland
28/09/2026
Phase III
Kardigan Inc.
Cardiovascular Diseases
Poland, Sweden, Belgium, France, Spain, Hungary, Denmark, Italy, Netherlands
28/09/2026
Phase III
Atsena Therapeutics Inc.
Eye Diseases
Italy, Germany, Spain, Netherlands, France, Belgium
28/09/2026
Phase III
GlaxoSmithKline Biologicals
Virus Diseases
Belgium, Germany, Finland, Spain
24/09/2026
Phase II
Unicancer
Neoplasms
Belgium
23/09/2026
Phase II
Use of the Checkpoint inhibitor DOstarlimab in the endOmetrial cancer fertility-Sparing trEatment: CHOOSE study.
2023-509535-11-00Newly diagnosed endometrial carcinomas of the MMR-deficient…
UZ Leuven
Neoplasms
Italy, Belgium
23/09/2026
Phase I
A clinical trial of MK-1824 in healthy participants (MK-1824-002)
2026-527518-22-00Heart failure with preserved ejection fraction
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Belgium
23/09/2026
Phase II
Agomab Spain S.L.U.
Digestive System Diseases
France, Germany, Poland, Spain, Czechia, Denmark, Austria, Italy, Belgium, Netherlands
21/09/2026
Phase III
Amgen Inc.
Nutritional and Metabolic Diseases
Czechia, Spain, Poland, Denmark, Germany, Italy, Belgium, Finland
21/09/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
Denmark, Netherlands, Italy, Spain, France, Portugal, Greece, Poland, Germany, Belgium, Norway, Czechia
21/09/2026
Phase III
Celea Therapeutics Inc.
Respiratory Tract Diseases
Greece, Italy, Czechia, France, Portugal, Denmark, Spain, Poland, Germany, Romania, Belgium, Netherlands
18/09/2026
Phase III
Aura Biosciences Inc.
Neoplasms
Austria, Netherlands, Belgium, Czechia, Spain, France, Germany, Italy
17/09/2026
Phase III
Pharmacosmos A/S
Neoplasms
Czechia, Greece, France, Belgium, Italy, Spain, Germany
17/09/2026
Phase III
Amgen Inc.
Digestive System Diseases
Belgium, Germany, Hungary, Czechia, Bulgaria, France, Netherlands, Italy, Poland, Greece, Portugal, Spain
16/09/2026
Phase IV
Attachment Development and Learning in ADHD: The Role of Dopamine.
2025-525122-35-00Attention-Deficit/Hyperactivity Disorder (ADHD)
UZ Leuven
Mental Disorders
Belgium
15/09/2026
Phase II
UZ Brussel
Neoplasms
Belgium
09/09/2026
Phase II
Kymera Therapeutics Inc.
Immune System Diseases
Austria, Germany, Belgium, Romania, Italy, Slovakia, Poland, Spain
09/09/2026
Phase III
Amgen Inc.
Neoplasms
Romania, Poland, Germany, Greece, Netherlands, Hungary, Portugal, France, Belgium, Italy, Spain
08/09/2026
Phase II
Argenx
Immune System Diseases
Germany, Estonia, Lithuania, Portugal, Slovakia, Hungary, Romania, Poland, Spain, Austria, Belgium, France, Bulgaria
08/09/2026
Phase I
F. Hoffmann-La Roche AG
Neoplasms
Spain, Poland, Romania, Hungary, Germany, Italy, Belgium, Netherlands, Denmark, France
07/09/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, Hungary, Sweden, Lithuania, Croatia, Netherlands, Slovakia, Poland, Austria, Norway, France, Italy, Bulgaria, Spain, Germany, Romania, Slovenia, Estonia, Portugal, Greece, Denmark
02/09/2026
Phase II
Dompe' Farmaceutici S.p.A.
Eye Diseases
Denmark, Italy, Germany, Hungary, Netherlands, Spain, Belgium, France, Portugal
01/09/2026
Phase III
Vaderis Therapeutics AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hungary, Netherlands, Germany, Bulgaria, France, Italy, Lithuania, Spain, Belgium
31/08/2026
Phase II
UZ Leuven
Neoplasms
Belgium
31/08/2026
Phase III
Biogen Idec Research Limited
Nervous System Diseases
Portugal, Italy, Belgium, Croatia, Hungary, Germany, Ireland, France, Norway, Poland
31/08/2026
Phase II
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Hemic and Lymphatic Diseases
Czechia, Denmark, Croatia, Spain, Sweden, Finland, Portugal, Ireland, Netherlands, Belgium, Norway
31/08/2026
Phase I
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Belgium
31/08/2026
Phase III
F. Hoffmann-La Roche AG
Neoplasms
France, Spain, Austria, Greece, Portugal, Ireland, Belgium, Italy, Poland, Germany, Netherlands
28/08/2026
Phase II
Contineum Therapeutics Inc.
Respiratory Tract Diseases
Italy, Belgium, Denmark, Austria, Greece, Germany, France, Netherlands, Portugal, Poland, Spain
26/08/2026
Phase II
Genmab A/S
Neoplasms
Italy, Belgium, France, Spain, Denmark, Netherlands, Germany
26/08/2026
Phase III
Harmony Biosciences Management Inc.
Nervous System Diseases
Belgium, Italy, Germany, France, Spain, Poland
25/08/2026
Phase I
ProQR Therapeutics VIII B.V.
Digestive System Diseases
Belgium
25/08/2026
Phase II
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Greece, Hungary, Poland, Belgium, Spain, Netherlands, Germany, France, Portugal, Italy, Romania
25/08/2026
Phase III
K-Group Beta Inc.
Neoplasms
Germany, Spain, Italy, Belgium, Poland, France, Ireland
21/08/2026
Phase I
A clinical trial of MK-8210 in healthy participants (MK-8210-001)
2026-527022-13-00HIV-1 (Human Immunodeficiency Virus Type 1)
Merck Sharp & Dohme LLC
Virus Diseases
Belgium
19/08/2026
Phase I/II
Terremoto Biosciences Inc.
Neoplasms
Spain, Ireland, Hungary, Romania, France, Portugal, Belgium, Poland
18/08/2026
Phase III
BioNTech SE
Male Urogenital Diseases
Belgium, Spain, Italy, Poland, Germany, Hungary
17/08/2026
Phase IV
Regeneron Pharmaceuticals Inc.
Respiratory Tract Diseases
Belgium, Italy, Spain
13/08/2026
Phase I
Incyte Corp.
Neoplasms
Italy, Belgium, Germany, France, Spain
10/08/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Netherlands, Belgium, Greece, Poland, Spain, Denmark, France, Bulgaria, Sweden
10/08/2026
Phase III
Argenx
Hormonal diseases
Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria
07/08/2026
Phase III
UZ Leuven
Cardiovascular Diseases
Belgium
06/08/2026
Phase III
AstraZeneca AB
Respiratory Tract Diseases
Denmark, Belgium, France, Italy, Netherlands, Austria, Poland
04/08/2026
Phase I
Incyte Corp.
Neoplasms
Italy, Belgium, Germany
03/08/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Skin and Connective Tissue Diseases
Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania
03/08/2026
Phase III
Janssen Cilag International
Immune System Diseases
Norway, Romania, Austria, Italy, Slovakia, Germany, Hungary, Netherlands, Belgium, France, Portugal, Czechia, Poland, Spain, Greece
03/08/2026
Phase III
Janssen Cilag International
Immune System Diseases
France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal
03/08/2026
Phase I
Immunic AG
Nervous System Diseases
Belgium
31/07/2026
Phase III
Perioperative Intravenous Metamizole in Laparoscopic Cholecystectomy: A rondomized, double blind, clinical trial.
2026-526531-18-00Post operative pain relief in Patients undergoing laparosco…
UZ Leuven
Anesthesia and Analgesia
Belgium
31/07/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Portugal, France, Slovakia, Bulgaria, Netherlands, Romania, Italy, Austria, Poland, Hungary, Spain, Czechia, Belgium
27/07/2026
Phase I
Merck Sharp & Dohme LLC
Parasitic Diseases
Belgium
27/07/2026
Phase III
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Italy, Greece, Spain, Belgium, France, Austria, Germany
27/07/2026
Phase III
Neurocrine Biosciences Inc.
Hormonal diseases
Czechia, Germany, Sweden, Portugal, Romania, Bulgaria, Italy, Austria, Spain, Belgium
23/07/2026
Phase III
Colchicine for the Reduction of Dependency and Vascular Events after an Acute Intracerebral Hemorrhage (CoVasc-ICH2)
2025-523435-18-00Major cardiovascular events (MACE), spontaneous intracerebr…
Hamilton Health Sciences Corporation, PHRI Population Health Research Institute International
Cardiovascular Diseases
Spain, Belgium
22/07/2026
Phase III
Ipsen Bioscience Inc.
Digestive System Diseases
Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway
21/07/2026
Phase II
Eli Lilly & Co.
Neoplasms
Belgium, France, Italy, Germany, Ireland
21/07/2026
Phase III
Novartis Pharma AG
Nervous System Diseases
Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary
20/07/2026
Phase III
Alkermes Inc.
Nervous System Diseases
Sweden, Finland, Belgium, Spain, Austria, Netherlands, France, Norway, Germany, Italy, Poland
20/07/2026
Phase II
Takeda Development Center Americas Inc.
Nervous System Diseases
Greece, Belgium, France, Germany
14/07/2026
Phase III
Merck Healthcare KGaA
Neoplasms
Belgium, Germany, France, Denmark, Poland, Spain, Netherlands, Italy, Austria
14/07/2026
Phase III
Revolution Medicines Inc.
Digestive System Diseases
Poland, Belgium, Norway, Sweden, Austria, Germany, Denmark, Netherlands, France, Italy, Spain
14/07/2026
Phase II
AstraZeneca AB
Immune System Diseases
France, Germany, Italy, Belgium, Poland, Spain
13/07/2026
Phase I/II
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Germany, Poland, Czechia, Belgium, France, Greece, Sweden, Portugal, Italy
13/07/2026
Phase I
A Phase 1, First-in-human, Dose Escalation Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
2026-525234-39-00Relapsed or Refractory higher-risk myelodysplastic syndrome…
Janssen Cilag International
Neoplasms
France, Spain, Germany, Denmark, Belgium
13/07/2026
Phase II
UZ Leuven
Female Urogenital Diseases and Pregnancy Complications
Belgium
10/07/2026
Phase II
Eisai Limited
Nervous System Diseases
Belgium, Italy, Spain, Germany
08/07/2026
Phase I
Atea Pharmaceuticals Inc.
Virus Diseases
Belgium
07/07/2026
Phase II
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Belgium, Ireland, Germany, Norway, Italy, France, Spain
07/07/2026
Phase IV
Sante et Prevoyance
Cardiovascular Diseases
Belgium
06/07/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Denmark, Sweden, Poland, Estonia, Portugal, Latvia, Spain, Hungary, Germany, Finland, Italy, Belgium, France
06/07/2026
Phase I
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Belgium
03/07/2026
Phase I
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
Belgium, Netherlands, Spain, Germany, Italy
01/07/2026
Phase III
Genmab A/S
Neoplasms
Finland, Belgium, Hungary, France, Denmark, Austria, Germany, Italy, Spain, Czechia, Norway, Poland
01/07/2026
Phase I
Pfizer Inc.
Nutritional and Metabolic Diseases
Belgium
01/07/2026
Phase III
Nuvation Bio Inc.
Respiratory Tract Diseases
Spain, Belgium, France, Italy, Germany
30/06/2026
Phase III
Insmed Inc.
Respiratory Tract Diseases
Greece, France, Italy, Belgium, Denmark, Germany, Poland, Czechia, Portugal, Austria, Spain, Romania
30/06/2026
Phase I/II
Ionis Pharmaceuticals Inc.
Nervous System Diseases
Spain, France, Belgium, Portugal, Germany
30/06/2026
Phase III
Merck Healthcare KGaA
Skin and Connective Tissue Diseases
Germany, Romania, France, Bulgaria, Belgium, Spain, Poland, Greece, Italy, Czechia
29/06/2026
Phase III
Merck Healthcare KGaA
Immune System Diseases
Spain, Belgium, France, Germany, Slovakia, Romania, Bulgaria, Italy, Poland, Greece
29/06/2026
Phase I/II
Revolution Medicines Inc.
Neoplasms
France, Poland, Ireland, Spain, Greece, Germany, Italy, Sweden, Belgium
29/06/2026
Phase III
Incyte Corp.
Neoplasms
Poland, Italy, Netherlands, Sweden, Denmark, Finland, Spain, France, Germany, Belgium, Norway, Austria
26/06/2026
Phase IV
UZ Leuven
Cardiovascular Diseases
Belgium
26/06/2026
Phase III
Adarx Pharmaceuticals Inc.
Immune System Diseases
Poland, Italy, Hungary, France, Austria, Czechia, Belgium, Spain, Bulgaria, Germany, Croatia
22/06/2026
Phase III
Zenas Biopharma (USA) LLC
Nervous System Diseases
Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia, Italy, Austria, Spain, Poland, France, Denmark, Hungary, Romania, Estonia, Slovakia, Belgium, Czechia, Norway, Lithuania, Greece, Slovenia
22/06/2026
Phase I
Regeneron Pharmaceuticals Inc.
Neoplasms
Belgium
22/06/2026
Phase I
Pfizer Inc.
Neoplasms
Belgium
17/06/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Respiratory Tract Diseases
Finland, Portugal, Hungary, Ireland, Poland, Greece, France, Belgium, Denmark, Italy, Spain, Netherlands, Austria, Germany
17/06/2026
Phase I
Incyte Corp.
Neoplasms
Italy, Belgium, Denmark
16/06/2026
Phase II
Spyre Therapeutics Inc.
Digestive System Diseases
Croatia, Poland, Austria, Czechia, Italy, Slovakia, Bulgaria, Greece, Belgium, Spain, Hungary, Germany, Lithuania, France, Romania
16/06/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Musculoskeletal Diseases
France, Netherlands, Germany, Czechia, Belgium, Austria, Hungary, Greece, Spain
15/06/2026
Phase IV
Swedish Orphan Biovitrum AB (publ)
Immune System Diseases
France, Italy, Spain, Germany, Austria, Belgium, Czechia
15/06/2026
Phase III
Glaxosmithkline Research & Development Limited
Nutritional and Metabolic Diseases
Greece, Germany, Belgium, Netherlands, Poland, Italy, France, Spain, Bulgaria, Austria
12/06/2026
Phase I/II
Verastem Inc.
Neoplasms
Italy, France, Germany, Belgium, Spain, Netherlands
09/06/2026
Phase IV
UZ Leuven
Nutritional and Metabolic Diseases
Belgium
08/06/2026
Phase III
Zai Lab (US) LLC
Neoplasms
Belgium, Czechia, Germany, Denmark, Greece, Netherlands, Poland, Spain, Austria, Italy, France, Croatia, Romania, Norway
08/06/2026
Phase I
Bayer Consumer Care AG
Neoplasms
Finland, Spain, Sweden, Italy, Denmark, Netherlands, Belgium
08/06/2026
Phase III
Alkermes Inc.
Nervous System Diseases
Spain, Netherlands, Belgium, Italy, France, Austria, Czechia, Germany, Sweden, Poland
04/06/2026
Phase I/II
GlaxoSmithKline Biologicals
Respiratory Tract Diseases
Belgium
04/06/2026
Phase III
Alkermes Inc.
Nervous System Diseases
Italy, France, Netherlands, Spain, Belgium, Austria, Czechia, Finland, Germany, Sweden, Norway, Poland
02/06/2026
Phase III
F. Hoffmann-La Roche AG
Hemic and Lymphatic Diseases
Hungary, Spain, Ireland, Poland, Austria, Germany, Denmark, Belgium, Netherlands, Italy, France
01/06/2026
Phase III
Novartis Pharma AG
Neoplasms
Belgium, Germany, Austria, Poland, Spain, Italy, Netherlands, Czechia, France
29/05/2026
Phase II
Vertex Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark
29/05/2026
Phase II
F. Hoffmann-La Roche AG
Immune System Phenomena
Italy, Spain, Germany, France, Denmark, Poland, Belgium
27/05/2026
Phase III
Janssen Cilag International
Immune System Diseases
Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary
27/05/2026
Phase III
Solid Biosciences Inc.
Musculoskeletal Diseases
Spain, Netherlands, France, Italy, Belgium, Germany
26/05/2026
Phase I/II
Merck Sharp & Dohme LLC
Neoplasms
France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia
26/05/2026
Phase III
Generate Biomedicines Inc.
Respiratory Tract Diseases
Italy, Slovakia, Spain, Ireland, Belgium, France, Estonia
26/05/2026
Phase I
A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants
2025-524564-38-00Neuropsychiatric indications and potentially other conditio…
Bristol-Myers Squibb Services Unlimited Company
Behavior and Behavior Mechanisms
Belgium
22/05/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
France, Ireland, Germany, Greece, Bulgaria, Spain, Netherlands, Italy, Sweden, Romania, Hungary, Belgium, Austria, Poland
22/05/2026
Phase II
Eikon Therapeutics Inc.
Neoplasms
Germany, Spain, Netherlands, Romania, Greece, Italy, Austria, Belgium, Bulgaria, France, Hungary, Poland
21/05/2026
Phase II
Pharming Technologies B.V.
Metabolism
Belgium, Germany, Czechia, Spain, Denmark, Italy, France, Netherlands
21/05/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Portugal, Greece, Germany, Hungary, France, Spain, Bulgaria, Slovakia, Poland, Czechia, Belgium, Italy, Romania, Denmark
20/05/2026
Phase III
Avidity Biosciences Inc.
Musculoskeletal Diseases
Italy, Germany, France, Spain, Belgium, Poland, Netherlands
20/05/2026
Phase I
F. Hoffmann-La Roche AG
Digestive System Diseases
Germany, Poland, Belgium
19/05/2026
Phase III
VarmX B.V.
Hemic and Lymphatic Diseases
Belgium, Germany, Italy, France, Czechia, Bulgaria, Hungary, Spain, Netherlands, Poland, Austria, Estonia, Romania, Portugal, Lithuania
19/05/2026
Phase II
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Nutritional and Metabolic Diseases
Portugal, Greece, Italy, Poland, Estonia, Slovakia, Sweden, Denmark, Belgium, Norway, Romania, France, Spain, Germany, Netherlands, Croatia
19/05/2026
Phase III
Incyte Corp.
Neoplasms
Poland, France, Denmark, Norway, Spain, Germany, Belgium, Netherlands, Austria, Italy
19/05/2026
Phase III
Zenas Biopharma (USA) LLC
Nervous System Diseases
Italy, Finland, Bulgaria, Greece, Belgium, Estonia, Portugal, Spain, Germany, France, Czechia, Slovakia, Romania, Croatia, Poland, Austria, Netherlands, Denmark, Sweden, Hungary
18/05/2026
Phase IV
UZ Leuven
Cardiovascular Diseases
Belgium
18/05/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Portugal, Norway, Sweden, Bulgaria, France, Belgium, Austria, Germany, Finland, Poland, Romania, Netherlands, Spain, Italy, Hungary, Czechia
15/05/2026
Phase III
Deciphera Pharmaceuticals Inc.
Nervous System Diseases
Czechia, Germany, Italy, Belgium, Spain, Poland, Austria, France, Hungary
14/05/2026
Phase IV
UZ Brussel
Reproductive and Urinary Physiological Phenomena
Belgium
13/05/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Portugal, Spain, Poland, Sweden, Italy, Czechia, France, Netherlands, Finland, Denmark, Austria, Germany, Belgium, Norway
13/05/2026
Phase II
Innocare Pharma Inc.
Skin and Connective Tissue Diseases
Belgium, Poland, Germany, France, Austria
13/05/2026
Phase I
A clinical trial of MK-1824 in healthy participants (MK-1824-001)
2026-525748-14-00Heart failure with preserved ejection fraction
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Belgium
12/05/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Czechia, Sweden, Poland, Netherlands, Greece, Latvia, Finland, Norway, Belgium, Austria, Portugal, Romania, Italy, Estonia, France, Ireland, Germany, Spain, Bulgaria, Hungary
12/05/2026
Phase III
Takeda Development Center Americas Inc.
Musculoskeletal Diseases
Germany, Belgium, Spain, Czechia, Croatia, Portugal, Poland, Latvia, Bulgaria, France, Estonia, Hungary, Italy
12/05/2026
Phase III
UZ Brussel
Bacterial Infections and Mycoses
Belgium
11/05/2026
Phase I
Regeneron Pharmaceuticals Inc.
Not possible to specify
Belgium
11/05/2026
Phase III
Eli Lilly & Co.
Neoplasms
Netherlands, Hungary, France, Austria, Poland, Italy, Denmark, Romania, Greece, Norway, Czechia, Belgium, Spain, Ireland, Germany
11/05/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Germany, Netherlands, Portugal, Denmark, Sweden, Finland, France, Spain, Austria, Italy, Hungary, Romania, Belgium, Czechia, Poland
11/05/2026
Phase III
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Poland, Hungary, France, Belgium, Italy, Netherlands, Czechia, Germany, Spain
07/05/2026
Phase I
Merck Sharp & Dohme LLC
Nervous System Diseases
Belgium
06/05/2026
Phase I
Amgen Inc.
Neoplasms
Spain, Germany, Poland, Belgium, France
05/05/2026
Phase II
Immunovant Sciences GmbH
Immune System Diseases
Italy, Greece, Germany, Hungary, Poland, Czechia, Netherlands, Spain, Belgium, Bulgaria, Latvia
05/05/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Denmark, France, Germany, Belgium
04/05/2026
Phase III
Novartis Pharma AG
Immune System Diseases
Belgium, France, Czechia, Croatia, Greece, Germany, Italy, Spain
04/05/2026
Phase I
Regeneron Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
Belgium, Czechia, Germany, Poland
30/04/2026
Phase I
Amgen Inc.
Neoplasms
Spain, France, Belgium
28/04/2026
Phase III
Inhibikase Therapeutics Inc.
Cardiovascular Diseases
Spain, Poland, Italy, Belgium, Latvia, Denmark, Czechia, Germany, France, Netherlands, Portugal, Ireland, Austria, Greece, Lithuania
28/04/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Czechia, Spain, Poland, Belgium, Finland, Germany, France, Netherlands, Hungary, Denmark
28/04/2026
Phase II
CSL Behring LLC
Hemic and Lymphatic Diseases
Belgium, Netherlands, France, Italy
28/04/2026
Phase I
Pfizer Inc.
Nervous System Diseases
Belgium
28/04/2026
Phase III
Dyne Therapeutics Inc.
Nervous System Diseases
Netherlands, Spain, Italy, Denmark, Germany, Belgium, France
28/04/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Slovakia, Austria, Spain, Romania, Portugal, Italy, Denmark, Belgium, Sweden, Poland, Netherlands, Croatia, Hungary, Bulgaria
28/04/2026
Phase II
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania
27/04/2026
Phase III
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Belgium, Germany, Bulgaria, France, Spain, Denmark, Italy, Netherlands
27/04/2026
Phase III
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Czechia, France, Romania, Germany, Poland, Bulgaria, Spain
27/04/2026
Phase I
Relative bioavailability and effect of food study with GLPG3667 in healthy subjects
2026-525706-35-00inflammatory and autoimmune diseases
Galapagos
Immune System Diseases
Belgium
27/04/2026
Phase III
Novartis Pharma AG
Nervous System Diseases
Netherlands, Germany, Spain, Italy, France, Belgium
21/04/2026
Phase II
CSL Behring LLC
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands
20/04/2026
Phase I
A study to test how well different doses of BI 3820768 are tolerated by people with advanced cancer (solid tumours)
2025-522913-45-00Advanced relapsed or refractory ovarian cancer, Advanced re…
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Spain, France, Belgium, Germany
20/04/2026
Phase I
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Hungary, Czechia, France, Italy, Belgium
20/04/2026
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Netherlands, Greece, Italy, Germany, Spain, Belgium, Sweden, France
20/04/2026
Phase III
Ferrer Internacional S.A., Prilenia Therapeutics B.V.
Nervous System Diseases
Belgium, Netherlands, Poland, France, Germany, Ireland, Italy, Sweden, Spain
20/04/2026
Phase III
Incyte Corp.
Neoplasms
Ireland, Poland, France, Netherlands, Spain, Italy, Germany, Belgium
17/04/2026
Phase III
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
France, Belgium, Germany, Italy, Bulgaria, Ireland, Lithuania, Norway, Romania, Hungary, Spain, Greece, Poland, Netherlands
17/04/2026
Phase III
UCB Biosciences Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Poland, France, Hungary, Belgium, Italy, Germany
15/04/2026
Phase II
Genmab A/S
Neoplasms
Germany, Hungary, Netherlands, France, Italy, Belgium, Spain, Poland
14/04/2026
Phase I
Merck Sharp & Dohme LLC
Immune System Diseases
Belgium
13/04/2026
Phase II
Kymera Therapeutics Inc.
Immune System Diseases
Spain, Romania, Slovakia, Poland, Germany, Italy, Belgium, Austria
10/04/2026
Phase II
Merus B.V.
Not possible to specify
Spain, Belgium, Netherlands, Poland, Italy, France
09/04/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Nervous System Diseases
Belgium, Spain, Italy
08/04/2026
Phase III
Belite Bio Inc.
Eye Diseases
Netherlands, France, Belgium
07/04/2026
Phase III
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Germany, Belgium, Netherlands, Denmark, Spain, Greece, Poland, Hungary, France, Italy, Bulgaria, Romania
07/04/2026
Phase III
Alfasigma S.p.A.
Musculoskeletal Diseases
Spain, Bulgaria, France, Belgium, Germany, Greece, Italy, Poland, Hungary, Czechia
07/04/2026
Phase III
Alfasigma S.p.A.
Immune System Diseases
France, Germany, Poland, Belgium, Hungary, Spain, Czechia, Greece, Italy
01/04/2026
Phase I/II
VectorY Therapeutics B.V.
Nervous System Diseases
Netherlands, Belgium, Spain
31/03/2026
Phase I/II
AstraZeneca AB
Neoplasms
Germany, Spain, France, Poland, Belgium, Netherlands, Italy
30/03/2026
Phase III
AstraZeneca AB
Pathological Conditions, Signs and Symptoms
Ireland, Greece, Czechia, France, Sweden, Belgium, Denmark, Spain, Italy, Germany
27/03/2026
Phase III
Genmab A/S
Neoplasms
Poland, Denmark, Finland, Lithuania, France, Germany, Spain, Belgium, Greece, Norway, Italy
26/03/2026
Phase IV
Fludarabine exposure in patients undergoing Fludarabine based lymphodepletion prior to CAR-T cell therapy
2025-524278-40-00Patients undergoing Fludarabine based lymphodepletion prior…
Universitair Ziekenhuis Gent
Hemic and Lymphatic Diseases
Belgium
23/03/2026
Phase IV
UZ Leuven
Nutritional and Metabolic Diseases
Belgium
19/03/2026
Phase II
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Belgium, France, Poland, Germany, Spain, Czechia
18/03/2026
Phase I
Pfizer Inc.
Immune System Diseases
Belgium
17/03/2026
Phase I
A clinical trial of MK-7228 in adults (MK-7228-002)
2025-522147-18-00Atherosclerosis
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Belgium
17/03/2026
Phase I/II
Medilink Therapeutics (Suzhou) Co. Ltd.
Neoplasms
Poland, Spain, France, Romania, Italy, Belgium, Hungary, Germany
17/03/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Male Urogenital Diseases
Germany, Croatia, Poland, Sweden, Portugal, Netherlands, Italy, Denmark, Slovakia, Spain, Norway, Romania, Belgium, Greece, France
17/03/2026
Phase III
Celldex Therapeutics Inc.
Skin and Connective Tissue Diseases
Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland
16/03/2026
Phase I
Immunic AG
Nervous System Diseases
Belgium
16/03/2026
Phase I
Boehringer Ingelheim International GmbH
Not possible to specify
Belgium
13/03/2026
Phase II
Zydus Therapeutics Inc.
Nervous System Diseases
Spain, Germany, Sweden, Ireland, Poland, Italy, Belgium, France, Netherlands
12/03/2026
Phase III
Liquidia Technologies Inc.
Respiratory Tract Diseases
Latvia, Germany, Italy, Czechia, France, Belgium, Portugal, Poland, Austria, Spain
11/03/2026
Phase I
Pfizer Inc.
Pathological Conditions, Signs and Symptoms
Belgium
11/03/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Sweden, Czechia, Belgium, Romania, Netherlands, Italy, France, Spain, Germany, Poland, Austria
10/03/2026
Phase I/II
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Neoplasms
Denmark, Belgium, Netherlands
10/03/2026
Phase III
Janssen Cilag International
Neoplasms
Belgium, Italy, Spain, Germany, France
09/03/2026
Phase III
Institute Of Tropical Medicine
Bacterial Infections and Mycoses
Belgium
06/03/2026
Phase II
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Belgium, Germany, Czechia, Netherlands, Spain, Austria, Italy, Greece, Croatia, Bulgaria, Poland, France, Romania, Hungary
06/03/2026
Phase I
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Belgium
06/03/2026
Phase IV
Vrije Universiteit Brussel
Anesthesia and Analgesia
Belgium
04/03/2026
Phase III
Novartis Pharma AG
Nervous System Diseases
Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway
03/03/2026
Phase III
Boehringer Ingelheim International GmbH
Respiratory Tract Diseases
Belgium, Spain, Netherlands, Italy, Germany, France
03/03/2026
Phase I
Merck Sharp & Dohme LLC
Nervous System Diseases
Belgium
02/03/2026
Phase II
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Poland, Italy, Belgium, Sweden, Hungary, France, Germany, Spain, Denmark
02/03/2026
Phase II
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Hungary, Spain, France, Belgium, Sweden, Germany, Italy
02/03/2026
Phase II
Zomagen Biosciences Limited
Cardiovascular Diseases
Belgium, France, Greece, Spain, Italy
27/02/2026
Phase III
AstraZeneca AB
Neoplasms
Spain, Poland, Hungary, Italy, Germany, France, Belgium, Austria
26/02/2026
Phase I
Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs
2025-523297-16-00Non-Hodgkin Lymphoid Malignancies (NHLs)
Janssen Cilag International
Neoplasms
Belgium, France, Spain
26/02/2026
Phase II
Elion Therapeutics Inc.
Bacterial Infections and Mycoses
Belgium, France, Spain, Italy
26/02/2026
Phase III
Eli Lilly & Co.
Cardiovascular Diseases
Germany, Czechia, Lithuania, Spain, Austria, France, Hungary, Greece, Estonia, Netherlands, Slovakia, Poland, Romania, Bulgaria, Italy, Belgium
24/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Spain, Czechia, Lithuania, Hungary, Greece, Bulgaria, Poland, Belgium, France, Germany, Norway, Austria, Netherlands, Italy, Slovakia
24/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Netherlands, Poland, Greece, Czechia, Italy, Bulgaria, Belgium, Germany, Lithuania, Austria, Spain, Hungary, Norway, France
24/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Hungary, Italy, Belgium, Czechia, Finland, Spain, Austria, Sweden, France, Denmark, Netherlands
23/02/2026
Phase III
Amgen Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Germany, Hungary, Italy, Belgium, Austria, Slovakia, Spain, Poland
23/02/2026
Phase III
Kura Oncology Inc.
Neoplasms
Belgium, Spain, Italy, Czechia, Hungary, Poland, France, Portugal, Germany, Greece
20/02/2026
Phase III
Olema Pharmaceuticals Inc.
Neoplasms
Hungary, Portugal, Italy, France, Poland, Czechia, Germany, Spain, Belgium, Austria, Romania, Greece, Netherlands
17/02/2026
Phase I
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, France, Hungary, Poland, Spain, Bulgaria
16/02/2026
Phase III
Syndax Pharmaceuticals Inc.
Neoplasms
Greece, Poland, Spain, Austria, Italy, Romania, Belgium, France, Lithuania, Germany, Hungary, Czechia, Portugal
13/02/2026
Phase III
Disc Medicine Inc.
Nutritional and Metabolic Diseases
Italy, France, Ireland, Belgium, Sweden, Germany, Netherlands, Norway, Spain
12/02/2026
Phase III
Regeneron Pharmaceuticals Inc.
Neoplasms
Greece, Spain, Poland, Italy, Austria, Czechia, Belgium, Germany, Netherlands, France
10/02/2026
Phase III
UZ Leuven
Cardiovascular Diseases
Belgium
09/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Germany, Austria, Italy, Czechia, Netherlands, Poland, Belgium, Hungary, Lithuania, Greece, France, Bulgaria, Spain, Norway
09/02/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Austria, France, Norway, Hungary, Bulgaria, Netherlands, Czechia, Slovakia, Germany, Lithuania, Greece, Belgium, Italy, Spain, Poland
09/02/2026
Phase IV
Rapid Oral Switch in Infectious Endocarditis, the ROSIE trial
2025-524484-20-00Infective Endocarditis
UZ Leuven
Bacterial Infections and Mycoses
Belgium
06/02/2026
Phase III
Glaxosmithkline Research & Development Limited
Neoplasms
France, Romania, Spain, Netherlands, Norway, Belgium, Hungary, Italy, Poland, Germany
06/02/2026
Phase I
AstraZeneca AB
Immune System Diseases
Germany, Spain, Belgium
03/02/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Finland, Germany, Italy, France, Sweden, Poland, Spain, Belgium, Czechia, Netherlands, Portugal, Norway
03/02/2026
Phase III
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Hungary, Czechia, Austria, Germany, France, Greece, Spain, Romania, Netherlands, Italy, Poland, Slovakia, Sweden, Portugal, Denmark, Bulgaria
03/02/2026
Phase I
A clinical study of MK-1045 in people with lupus or rheumatoid arthritis (MK-1045-004)
2025-523412-36-00Systemic lupus erythematosus, Rheumatoid arthritis
Merck Sharp & Dohme LLC
Immune System Diseases
Italy, Belgium, Romania, Spain
02/02/2026
Phase II
Sab Biotherapeutics Inc.
Nutritional and Metabolic Diseases
Austria, Germany, Poland, Italy, Denmark, Spain, Belgium, Finland, France, Lithuania, Slovenia
02/02/2026
Phase III
Kardigan Inc.
Cardiovascular Diseases
Spain, Denmark, Belgium, Hungary, Italy, Poland, France, Sweden, Netherlands
30/01/2026
Phase I/II
Sarepta Therapeutics Inc.
Nervous System Diseases
Spain, Germany, Belgium, Italy
29/01/2026
Phase III
Ideaya Biosciences Inc.
Eye Diseases
France, Spain, Poland, Italy, Czechia, Belgium, Austria, Netherlands, Denmark, Germany, Slovenia
29/01/2026
Phase III
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Czechia, France, Netherlands, Bulgaria, Norway, Austria, Poland, Spain, Italy, Hungary, Germany, Romania, Sweden, Portugal, Belgium
27/01/2026
Phase IV
UZ Leuven
Nervous System Diseases
Netherlands, Belgium
27/01/2026
Phase III
Insmed Inc.
Respiratory Tract Diseases
Portugal, Italy, Czechia, Poland, Denmark, Greece, Germany, Romania, Spain, France, Belgium, Austria
26/01/2026
Phase III
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Germany, Spain, Belgium, Czechia, Norway, France, Poland, Netherlands, Italy, Finland
26/01/2026
Phase IV
CHU Saint Pierre
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Belgium
26/01/2026
Phase II
F. Hoffmann-La Roche AG
Neoplasms
Belgium, Spain
23/01/2026
Phase III
Arrowhead Pharmaceuticals Inc.
Cardiovascular Diseases
Greece, France, Belgium, Germany, Netherlands, Austria, Sweden, Spain, Czechia, Italy
23/01/2026
Phase II
Satellos Bioscience Inc.
Nervous System Diseases
Spain, Belgium, Poland
22/01/2026
Phase III
Evaluation of a New Pain Management Regime for Oocyte Pick-Up During Fertility Treatment
2025-523018-10-00Acute procedural pain associated with oocyte pick-up (oocyt…
UZ Brussel
Anesthesia and Analgesia
Belgium
22/01/2026
Phase II
UZ Leuven
Physiological processes
Belgium
21/01/2026
Phase IV
The effect op corticosteroids on quality of life following total hip arthroplasty: HIPSTER study
2025-524368-39-00Patients aged 60 years or older undergoing total hip arthro…
Ziekenhuis Oost Limburg
Anesthesia and Analgesia
Belgium
21/01/2026
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Austria, Portugal, Netherlands, Greece, Belgium, Spain, Germany, France, Romania, Sweden, Italy, Denmark
19/01/2026
Phase III
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Romania, Bulgaria, Germany, Spain, Czechia, France, Hungary, Italy, Sweden, Poland, Denmark, Belgium
19/01/2026
Phase IV
CHU Saint Pierre
Respiratory Tract Diseases
Belgium
19/01/2026
Phase III
Sanofi-Aventis Recherche & Developpement
Hemic and Lymphatic Diseases
Belgium, Italy, Romania, Germany, Hungary, Spain, Poland
15/01/2026
Phase III
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Neoplasms
Belgium, Netherlands, Germany, Austria, Denmark, Estonia, Finland, Ireland, Italy, Lithuania, Spain, Sweden, Norway, Poland
15/01/2026
Phase III
Janssen Cilag International
Neoplasms
Italy, Portugal, Spain, Romania, Hungary, France, Czechia, Germany, Netherlands, Austria, Poland, Belgium
14/01/2026
Phase II
AstraZeneca AB
Not possible to specify
Germany, France, Spain, Italy, Belgium, Czechia, Greece, Denmark, Hungary
14/01/2026
Phase III
Exelixis Inc.
Neoplasms
France, Poland, Netherlands, Belgium, Germany, Spain, Italy, Austria
09/01/2026
Phase III
Eli Lilly & Co.
Immune System Diseases
Belgium, Spain, Norway, Germany, Sweden, Netherlands, France, Italy, Finland, Portugal, Poland
23/12/2025
Phase III
Mirum Pharmaceuticals Inc.
Virus Diseases
Belgium, Hungary, Bulgaria
22/12/2025
Phase I/II
Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer
2025-520467-40-00High-risk non-muscle invasive bladder cancer (NMIBC) with c…
Merck Sharp & Dohme LLC
Neoplasms
Belgium, Greece, Austria, Spain, Norway, Netherlands, Italy, France
22/12/2025
Phase III
Pfizer Inc.
Not possible to specify
Belgium, Finland, France, Germany, Netherlands, Bulgaria, Spain, Slovakia, Italy, Czechia, Poland, Greece
22/12/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Male Urogenital Diseases
Ireland, Belgium, Germany, Italy, Norway, Spain, Austria, Sweden, France, Romania, Czechia
19/12/2025
Phase III
Groupe Oncologie Radiotherapie Tete Cou
Neoplasms
France, Spain, Belgium
18/12/2025
Phase III
Biohaven Therapeutics Ltd.
Nervous System Diseases
Germany, France, Italy, Belgium, Czechia, Poland, Austria, Netherlands, Spain, Portugal
15/12/2025
Phase IV
Ziekenhuis Oost Limburg
Cardiovascular Diseases
Belgium
12/12/2025
Phase III
Crinetics Pharmaceuticals Inc.
Hormonal diseases
Italy, Germany, France, Belgium, Netherlands, Poland
09/12/2025
Phase III
Novo Nordisk A/S
Cardiovascular Diseases
Germany, France, Belgium, Italy, Denmark, Netherlands, Spain, Czechia, Sweden
09/12/2025
Phase III
Charite Universitaetsmedizin Berlin KöR
Hemic and Lymphatic Diseases
Netherlands, Czechia, Italy, Spain, Denmark, Austria, Norway, Sweden, Germany, France, Finland, Belgium, Slovenia
09/12/2025
Phase II
Novartis Pharma AG
Hemic and Lymphatic Diseases
Germany, Czechia, Belgium, Spain, Italy, Bulgaria, Romania, France, Hungary
08/12/2025
Phase III
Bayer AG
Cardiovascular Diseases
Czechia, Germany, Greece, Italy, Finland, Bulgaria, Belgium, Poland, Austria, Portugal, Spain, Hungary, Sweden
05/12/2025
Phase III
Bayer AG
Cardiovascular Diseases
Czechia, Poland, Portugal, Austria, Finland, Greece, Bulgaria, Sweden, Spain, Italy, Belgium, Hungary, Germany
05/12/2025
Phase III
Zealand Pharma A/S
Digestive System Diseases
Finland, France, Belgium, Germany, Hungary, Spain, Austria, Netherlands, Italy, Denmark, Czechia, Norway, Poland, Sweden, Estonia
04/12/2025
Phase IV
Centre hospitalier universitaire de Liege
Virus Diseases
Belgium
04/12/2025
Phase III
AbbVie Deutschland GmbH & Co. KG
Eye Diseases
Czechia, Portugal, Hungary, Spain, Belgium, Italy, Austria, France, Slovakia, Croatia, Germany, Bulgaria, Greece
02/12/2025
Phase II
Pfizer Inc.
Cardiovascular Diseases
Italy, Czechia, Germany, Greece, Spain, Belgium, France
02/12/2025
Phase III
Janssen Cilag International
Immune System Diseases
Netherlands, Italy, Portugal, Spain, Czechia, Romania, France, Sweden, Hungary, Belgium, Germany, Greece, Poland
01/12/2025
Phase III
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Czechia, Germany, Sweden, Greece, Croatia, Belgium, Poland, Spain, Portugal, Italy, Denmark, France, Netherlands
01/12/2025
Phase II
Shionogi B.V.
Nutritional and Metabolic Diseases
Belgium, Germany, Denmark, France, Italy, Spain, Netherlands
01/12/2025
Phase II
Vertex Pharmaceuticals Inc.
Genetic Phenomena
France, Germany, Italy, Belgium, Spain, Netherlands
28/11/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Czechia, Austria, Belgium, Ireland, Spain, Germany, Romania, Netherlands, Slovakia, Greece, Poland, Italy, Denmark, France, Sweden
28/11/2025
Phase II
Janssen Cilag International
Neoplasms
Germany, Spain, Finland, Greece, Portugal, Italy, Belgium, Poland, France
27/11/2025
Phase III
UZ Brussel
Female Urogenital Diseases and Pregnancy Complications
Belgium
26/11/2025
Phase III
Diamedica Therapeutics Inc.
Nervous System Diseases
Romania, Hungary, Belgium, Poland, Spain, France
25/11/2025
Phase III
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Slovakia, Denmark, France, Sweden, Ireland, Belgium, Netherlands, Spain, Croatia, Germany, Poland, Hungary, Norway, Portugal
24/11/2025
Phase II
F. Hoffmann-La Roche AG
Immune System Phenomena
Italy, Denmark, France, Poland, Germany, Spain, Belgium
23/11/2025
Phase II
Imbria Pharmaceuticals Inc.
Cardiovascular Diseases
Austria, Germany, Belgium, France, Portugal, Spain, Netherlands, Italy, Poland
20/11/2025
Phase III
BeOne Medicines AG
Neoplasms
Sweden, Belgium, Spain, Germany, Austria, Netherlands, Italy, Romania, Poland, France
18/11/2025
Phase III
Janssen Cilag International
Neoplasms
France, Belgium, Spain, Poland, Italy, Netherlands, Germany
18/11/2025
Phase III
Pfizer Inc.
Neoplasms
Greece, Italy, Belgium, Slovakia, Czechia, Germany, France, Poland, Denmark, Spain, Netherlands, Sweden, Finland, Bulgaria
17/11/2025
Phase III
AstraZeneca AB
Neoplasms
Italy, Netherlands, Lithuania, Finland, Greece, Austria, Belgium, Hungary, Spain, Poland, Czechia, Germany, France, Denmark, Slovenia
17/11/2025
Phase III
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL.
2025-522052-13-00Framework for Optimizing, Refining, and Unifying Management…
Ospedale Pediatrico Bambino Gesu
Hemic and Lymphatic Diseases
Germany, Denmark, Finland, Norway, Austria, Italy, Poland, France, Czechia, Belgium, Croatia, Hungary, Lithuania, Sweden, Netherlands, Slovakia, Spain
17/11/2025
Phase I
Regeneron Pharmaceuticals Inc.
Nervous System Diseases
Netherlands, Belgium
17/11/2025
Phase I
Boehringer Ingelheim International GmbH
Neoplasms
Belgium, Netherlands
14/11/2025
Phase III
AstraZeneca AB
Male Urogenital Diseases
Austria, Sweden, Spain, France, Netherlands, Germany, Belgium, Finland, Hungary, Poland, Italy
12/11/2025
Phase I
A clinical study of MK-6050 in healthy people (MK-6050-001)
2025-523861-58-00Hidradenitis suppurativa
Merck Sharp & Dohme LLC
Immune System Diseases
Belgium
12/11/2025
Phase III
Relay Therapeutics Inc.
Neoplasms
Hungary, Spain, Italy, Belgium, Netherlands, Austria, Germany, Greece, Czechia, Denmark, Poland, Bulgaria, Portugal, France, Ireland, Romania
11/11/2025
Phase II
Spyre Therapeutics Inc.
Digestive System Diseases
Belgium, Hungary, Lithuania, Netherlands, Croatia, Czechia, Bulgaria, Romania, Spain, France, Austria, Italy, Greece, Poland, Germany, Slovakia
10/11/2025
Phase IV
Ziekenhuis Oost Limburg
Cardiovascular Diseases
Belgium
10/11/2025
Phase III
Merck Sharp & Dohme LLC
Neoplasms
Greece, Germany, France, Italy, Croatia, Denmark, Czechia, Austria, Belgium, Ireland, Spain, Poland
10/11/2025
Phase III
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Nutritional and Metabolic Diseases
Spain, Germany, Portugal, Netherlands, Belgium, Poland, Italy, France, Sweden, Hungary
06/11/2025
Phase II
Xylocor Therapeutics Inc.
Cardiovascular Diseases
Belgium, Poland, Hungary, Netherlands, Germany
04/11/2025
Phase III
Europese Organisatie Voor Onderzoek En Behandeling Van Kanker Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer European Organi
Neoplasms
Germany, France, Italy, Austria, Netherlands, Spain, Czechia, Belgium
04/11/2025
Phase III
Fondazione Penta Ets
Respiratory Tract Diseases
Belgium, Netherlands
04/11/2025
Phase III
Amgen Inc.
Neoplasms
Austria, Netherlands, Portugal, Spain, Belgium, Greece, France, Italy, Germany
03/11/2025
Phase I/II
Glaxosmithkline Research & Development Limited
Neoplasms
Estonia, Czechia, Spain, Romania, Italy, Denmark, Belgium, Greece
03/11/2025
Phase II
AstraZeneca AB
Respiratory Tract Diseases
Netherlands, Italy, Greece, Denmark, Belgium, Spain, France, Germany
31/10/2025
Phase III
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Neoplasms
Netherlands, Belgium
28/10/2025
Phase I
Amgen Inc.
Neoplasms
France, Netherlands, Germany, Denmark, Spain, Italy, Belgium
28/10/2025
Phase IV
Gentofte Hospital, Austin Health
Immune System Diseases
Belgium, Denmark
28/10/2025
Phase II
Immunovant Sciences GmbH
Immune System Diseases
Austria, Hungary, Slovenia, Greece, Denmark, Ireland, Finland, Estonia, Spain, Slovakia, Netherlands, Poland, Norway, Italy, Portugal, Belgium, Germany, Romania, Bulgaria
28/10/2025
Phase III
BioNTech SE
Female Urogenital Diseases and Pregnancy Complications
Denmark, Poland, Italy, Finland, Czechia, Sweden, Greece, Belgium, Norway, Hungary, Germany, Austria, France, Spain, Netherlands
27/10/2025
Phase I
Xencor Inc.
Neoplasms
Spain, France, Belgium, Denmark
27/10/2025
Phase III
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Greece, Czechia, France, Sweden, Romania, Belgium, Austria, Bulgaria, Italy, Netherlands, Denmark, Germany, Poland, Hungary, Spain, Norway
24/10/2025
Phase III
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Netherlands, Spain, France, Belgium, Sweden, Germany, Poland, Italy
24/10/2025
Phase III
Eidos Therapeutics Inc.
Cardiovascular Diseases
Germany, Portugal, Netherlands, France, Spain, Italy, Ireland, Belgium, Sweden, Denmark, Greece
22/10/2025
Phase III
UZ Brussel
Diagnosis
Belgium
22/10/2025
Phase III
Adarx Pharmaceuticals Inc.
Immune System Diseases
Belgium, Poland, Italy, Czechia, Hungary, Spain, Germany, Croatia, France, Bulgaria, Austria
22/10/2025
Phase II
Scholar Rock Inc.
Musculoskeletal and Neural Physiological Phenomena
Belgium, France, Italy, Spain, Netherlands
21/10/2025
Rows per page Showing 1–456 of 456
1
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 November 2026. https://priyalifescience.com/clinical-trials-europe/country/belgium

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,893 trial records at the last sync on 20 Nov 2026, 03:17 UTC; this register shows the 2,556 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 456 of those trials with a site in Belgium.

How many recently authorised EU trials have a site in Belgium?

456 of the 2,556 most recently authorised trials in this register list a site in Belgium; 236 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase (Belgium), 456 trials
PhaseTrialsShare
Phase III23651.8%
Phase II9220.2%
Phase I7215.8%
Phase I/II316.8%
Phase IV255.5%

Most active sponsors

Lead sponsors with the most trials (Belgium)
Lead sponsorTrials
Merck Sharp & Dohme LLC26
UZ Leuven20
Sanofi-Aventis Recherche & Developpement18
AstraZeneca AB16
Eli Lilly & Co.16
Pfizer Inc.16
Regeneron Pharmaceuticals Inc.14
Janssen Cilag International13
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.12
Novartis Pharma AG12
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.